Biblio
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol. 2024.
Chimeric Antigen Receptor T Therapy for Adult B-Cell Acute Lymphoblastic Leukemia: State-of the-(C)ART and Road Ahead. Blood Adv. 2023.
. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2019.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024.
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020;7(7):e523-e533.
Immunofluorescence staining with an antipromyelocytic leukemia antibody for a rapid diagnosis of acute promyelocytic leukemia. Hematol Oncol Stem Cell Ther. 2016.
. Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia. Am J Hematol. 2021.
Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. Hematol Oncol Stem Cell Ther. 2016.
. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2015.
Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine. Am J Hematol. 2021.
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol. 2023.
A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood Adv. 2024.
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022:JCO2102823.
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019.
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in Class Rearrangements. JCO Precis Oncol. 2023;7:e2200707.